MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
Triple Helix: Global Regional Innovation Clusters (RICs)
*Triple Helix Cluster & Developments: North America
*Triple Helix Cluster & Developments: Canada
Industry: Canada
Xenon Pharmaceuticals Inc (NASDAQ: XENE)
Organization & Developments: Xenon Pharmaceuticals
Parents
Xenon Pharmaceuticals Inc (NASDAQ: XENE)
Children
*Clinical genetics-based drug development company
*The company has built a core platform, which is called Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies
*The partnership with Genentech to develop orally active selective small molecule inhibitors of Nav1.7 for the treatment of pain is also progressing.
*Xenon has collaborations with drug giant Teva Pharmaceuticals (NYSE:TEVA) and Genentech focused on development of novel Nav1.7 inhibitors for the treatment of pain.
*Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases.
2012: Roche Signs $646 Million Pain Pact With Xenon (2012)
2016: Biotech Forum Daily Digest: Spotlight On Xenon. Biotech Posts Strong Week. Acadia Benefiting From Possible M&A Uptick
2017: Biotech Forum Daily Digest - Celgene Continues To Make Deals, Spotlight On Xenon
2018: Xenon: An Updated Investment Analysis_seekingalpha.com
2019: Xenon Pharmaceuticals: Updates To Thesis, Pipeline Progressing - Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
2020: Xenon Pharmaceuticals Is Poised For Significant Progress In 2020_seekingalpha.com
2020: Xenon Pharmaceuticals: Updates To Thesis, Low Valuation With Multiple Catalysts In 2021
2022: Putting Xenon Pharmaceuticals Back In The Spotlight_seekingalpha.com
2023: Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip_ seekingalpha.com
2024: Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
2024: Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
2025: Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Jumps
*Key People: Xenon Pharmaceuticals
Finance & Acquisitions: Xenon Pharmaceuticals